[go: up one dir, main page]

PE20100658A1 - COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y UN ADYUVANTE QUE CONTIENE QS21, COLESTEROL Y 3D-MPL - Google Patents

COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y UN ADYUVANTE QUE CONTIENE QS21, COLESTEROL Y 3D-MPL

Info

Publication number
PE20100658A1
PE20100658A1 PE2010000522A PE2010000522A PE20100658A1 PE 20100658 A1 PE20100658 A1 PE 20100658A1 PE 2010000522 A PE2010000522 A PE 2010000522A PE 2010000522 A PE2010000522 A PE 2010000522A PE 20100658 A1 PE20100658 A1 PE 20100658A1
Authority
PE
Peru
Prior art keywords
vzv
mpl
composition including
cholesterol
immunogenic composition
Prior art date
Application number
PE2010000522A
Other languages
English (en)
Inventor
Emmanuel Jules Hanon
Jean Stephenne
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34430592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20100658(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20100658A1 publication Critical patent/PE20100658A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

REFERIDA A UNA COMPOSICION INMUNOGENA O VACUNA QUE COMPRENDE UN ANTIGENO gp1 (gE) DEL VIRUS DE LA VARICELA ZOSTER (VZV) TRUNCADO PARA ELIMINAR LA REGION DEL ANCLAJE DEL CARBOXILO TERMINAL EN COMBINACION CON UN ADYUVANTE QUE COMPRENDE UNA FRACCION PURIFICADA POR HPLC DE QUIL A (DERIVADO DE LA CORTEZA DEL ARBOL DE SUDAMERICA QUILLAJA SAPONARIA MOLINA) QS21, MONOFOSFORIL LIPIDO A 3-O-DESACILADO (3D-MPL) Y LIPOSOMAS QUE COMPRENDEN COLESTEROL, DONDE EL gp1 CONSISTE EN UNA SECUENCIA DE AMINOACIDOS SEQ ID No:1
PE2010000522A 2005-03-03 2006-03-01 COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y UN ADYUVANTE QUE CONTIENE QS21, COLESTEROL Y 3D-MPL PE20100658A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0504436.7A GB0504436D0 (en) 2005-03-03 2005-03-03 Vaccine

Publications (1)

Publication Number Publication Date
PE20100658A1 true PE20100658A1 (es) 2010-10-23

Family

ID=34430592

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2006000237A PE20061287A1 (es) 2005-03-03 2006-03-01 COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y EL ADYUVANTE TH-1
PE2010000522A PE20100658A1 (es) 2005-03-03 2006-03-01 COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y UN ADYUVANTE QUE CONTIENE QS21, COLESTEROL Y 3D-MPL

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2006000237A PE20061287A1 (es) 2005-03-03 2006-03-01 COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y EL ADYUVANTE TH-1

Country Status (35)

Country Link
US (3) US20080171079A1 (es)
EP (4) EP2301955B1 (es)
JP (2) JP5420842B2 (es)
KR (2) KR101357204B1 (es)
CN (2) CN101189254B (es)
AR (2) AR052498A1 (es)
AU (1) AU2006222225B2 (es)
BE (1) BE2018C035I2 (es)
BR (1) BRPI0607840B1 (es)
CA (2) CA2882255C (es)
CY (5) CY1116108T1 (es)
DK (4) DK2281831T3 (es)
EA (1) EA011884B1 (es)
ES (4) ES2675055T3 (es)
GB (1) GB0504436D0 (es)
HR (4) HRP20150142T1 (es)
HU (4) HUE038468T2 (es)
IL (1) IL185442A (es)
LT (4) LT2301955T (es)
LU (1) LUC00087I2 (es)
MA (1) MA29714B1 (es)
MX (2) MX2007010626A (es)
MY (1) MY148464A (es)
NL (1) NL300951I2 (es)
NO (2) NO341841B1 (es)
NZ (1) NZ561075A (es)
PE (2) PE20061287A1 (es)
PL (4) PL2301955T3 (es)
PT (4) PT2281831T (es)
SI (4) SI2281831T1 (es)
TR (2) TR201809393T4 (es)
TW (1) TWI403517B (es)
UA (1) UA94900C2 (es)
WO (1) WO2006094756A2 (es)
ZA (1) ZA200707144B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US20100330122A1 (en) * 2007-07-19 2010-12-30 Gale Smith VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES (VLPs) AND ANTIGENS
FR2952825B1 (fr) 2009-11-24 2012-05-25 Goaster Jacqueline Le Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2
US9801897B2 (en) 2010-07-06 2017-10-31 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
CA2804492A1 (en) 2010-07-06 2012-01-12 Novartis Ag Immunisation of large mammals with low doses of rna
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
EP4226941B1 (en) 2010-08-31 2024-10-23 GlaxoSmithKline Biologicals SA Pegylated liposomes for delivery of immunogen-encoding rna
KR102162111B1 (ko) 2010-10-11 2020-10-07 노파르티스 아게 항원 전달 플랫폼
EP3332802A1 (en) 2011-07-06 2018-06-13 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
TW201601750A (zh) 2013-10-03 2016-01-16 Nitto Denko Corp 注射疫苗組合物
JP6499420B2 (ja) * 2014-11-13 2019-04-10 公益財団法人ヒューマンサイエンス振興財団 ワクチン及び感染防御キット
BE1022523B1 (fr) * 2014-12-18 2016-05-20 Glaxosmithkline Biologicals Sa Vaccination
EP3233118A1 (en) * 2014-12-18 2017-10-25 GlaxoSmithKline Biologicals S.A. Vaccination
PT3718565T (pt) 2015-10-22 2022-07-20 Modernatx Inc Vacinas contra vírus respiratórios
TW201729838A (zh) * 2015-10-22 2017-09-01 現代公司 用於水痘帶狀疱疹病毒 (vzv)之核酸疫苗
IL286493B (en) 2015-11-06 2022-07-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogues, methods of producing same, compositions comprising same and uses thereof
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
CN110035772B (zh) * 2016-11-25 2023-07-18 财团法人牧岩生命科学研究所 水痘带状疱疹病毒疫苗
WO2018097642A1 (ko) * 2016-11-25 2018-05-31 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
CN107022559A (zh) * 2016-12-08 2017-08-08 长春祈健生物制品有限公司 一种水痘‑带状疱疹病毒糖蛋白e胞外区蛋白的制备方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
KR102034234B1 (ko) * 2016-12-26 2019-10-18 재단법인 목암생명과학연구소 대상포진 백신 조성물
CN108727503A (zh) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV重组gE-鞭毛素融合蛋白及其制备方法和应用
CA3061205A1 (en) * 2017-04-25 2018-11-01 Adjuvance Technologies, Inc. Triterpene saponin analogues
US20200164065A1 (en) * 2017-04-25 2020-05-28 Adjuvance Technologies, Inc. Triterpene saponin analogues
US20210187098A1 (en) * 2017-04-28 2021-06-24 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
IE87414B1 (en) 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
AU2018350887A1 (en) 2017-10-16 2020-03-05 Adjuvance Technologies, Inc. Triterpene saponin analogues
CN111670044A (zh) 2017-12-01 2020-09-15 葛兰素史密丝克莱恩生物有限公司 皂苷纯化
CN108315344A (zh) * 2018-02-14 2018-07-24 武汉博沃生物科技有限公司 Vzv糖蛋白e基因表达载体及其重组酵母菌株与应用
KR102337922B1 (ko) 2018-04-19 2021-12-09 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
KR20190121956A (ko) 2018-04-19 2019-10-29 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
AU2019272184B2 (en) 2018-05-23 2022-01-27 Mogam Institute For Biomedical Research Antigen variant of varicella zoster virus and use thereof
WO2020030572A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
CN108992667A (zh) * 2018-08-09 2018-12-14 安徽智飞龙科马生物制药有限公司 一种带状疱疹疫苗及其制备方法、应用
KR102270048B1 (ko) * 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
CN113164586B (zh) * 2018-09-27 2024-04-16 武汉博沃生物科技有限公司 免疫组合物及其制备方法与应用
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CN109602901B (zh) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
CN112138153B (zh) * 2019-06-28 2022-08-23 怡道生物科技(苏州)有限公司 一种重组带状疱疹疫苗组合物及其用途
CN112142828B (zh) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 一种gE基因及表达该基因的载体
AU2020403296B2 (en) * 2019-12-13 2025-03-06 Grand Theravac Life Science (Nanjing) Co., Ltd. Immunostimulatory composition and use thereof
US20230110839A1 (en) * 2020-02-28 2023-04-13 Celltrion Inc. Varicella zoster virus fusion protein and immunogenic composition comprising same
MX2023001586A (es) 2020-08-07 2023-05-03 Access To Advanced Health Inst Saponinas purificadas y proceso cromatografico para purificacion de las mismas.
EP4212173A4 (en) * 2020-09-11 2024-10-23 Eubiologics Co., Ltd. Vaccine composition for chickenpox or varicella zoster and method of using same
RU2750818C1 (ru) * 2020-11-19 2021-07-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова Вирусный штамм для получения аттенуированной живой культуральной вакцины для профилактики и лечения опоясывающего герпеса для взрослого населения
WO2023056912A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for vzv
WO2023064612A2 (en) 2021-10-15 2023-04-20 BioNTech SE Pharmaceutical compositions for delivery of viral antigens and related methods
JP2024541466A (ja) 2021-11-24 2024-11-08 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 水痘帯状疱疹ウイルス免疫原組成物及びその使用
CN116327912A (zh) * 2021-12-23 2023-06-27 上海泽润生物科技有限公司 带状疱疹疫苗组合物
CN116350770B (zh) * 2021-12-28 2024-07-12 成都迈科康生物科技有限公司 一种带状疱疹疫苗制剂及其制备方法
EP4558170A1 (en) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Continuous process for vaccine production
CN116655748B (zh) * 2023-02-28 2024-07-26 易慧生物技术(上海)有限公司 一种截短型水痘-带状疱疹病毒gE蛋白及其应用
CN118240844B (zh) * 2024-05-27 2024-12-13 北京悦康科创医药科技股份有限公司 带状疱疹mRNA疫苗及其制备方法和应用
WO2026006687A1 (en) * 2024-06-28 2026-01-02 Orbital Therapeutics, Inc. Circular rna compositions and uses thereof for diseases caused by varicella-zoster virus
CN120081913B (zh) * 2025-05-08 2025-08-12 江苏华诺泰生物医药科技有限公司 一种重组带状疱疹病毒原液的纯化方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202B2 (es) * 1974-03-12 1978-11-01
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0405867B1 (en) 1989-06-27 1995-03-15 SMITHKLINE BEECHAM BIOLOGICALS s.a. Novel compounds
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
KR100278157B1 (ko) * 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
EP0651789B2 (en) * 1992-07-17 2009-05-20 Merck & Co. Inc. Method for preventing zoster and alleviating varicella related post-herpetic neuralgia
CZ289476B6 (cs) 1993-03-23 2002-01-16 Smithkline Beecham Biologicals (S.A.) Očkovací přípravek a způsob jeho výroby
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AU696775B2 (en) * 1995-03-23 1998-09-17 Kirin-Amgen, Inc. IL-17 receptor
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
KR0177323B1 (ko) * 1996-02-16 1999-04-01 성재갑 바이러스 백신 생산에 유용한 사람 이배체 폐세포 및 이를 이용한 수두 백신의 제조방법
BR9811262A (pt) 1997-04-01 2000-10-17 Ribi Immunochem Research Inc Composições auxiliares imunológicas aquosas de lipìdio de monofosforila a.
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
GB9901254D0 (en) * 1999-01-20 1999-03-10 Smithkline Beecham Biolog Vaccines
CZ302449B6 (cs) * 2000-10-18 2011-05-25 Glaxosmithkline Biologicals S. A. Vakcinacní prostredky
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
CY1121211T1 (el) 2020-05-29
LUC00087I2 (es) 2018-11-26
DK2301955T3 (en) 2018-06-14
MA29714B1 (fr) 2008-09-01
CY1118629T1 (el) 2017-07-12
SI2281831T1 (en) 2018-07-31
SI2301955T1 (en) 2018-07-31
EP2281831A3 (en) 2011-11-16
CY2018025I1 (el) 2018-12-12
AR052498A1 (es) 2007-03-21
CA2882255C (en) 2018-03-27
EA011884B1 (ru) 2009-06-30
JP2013144710A (ja) 2013-07-25
TW200643028A (en) 2006-12-16
GB0504436D0 (en) 2005-04-06
PT1858917E (pt) 2015-02-24
EA200701632A1 (ru) 2008-02-28
TWI403517B (zh) 2013-08-01
PE20061287A1 (es) 2006-12-07
CA2882255A1 (en) 2006-09-14
PT2301955T (pt) 2018-06-18
LT2281830T (lt) 2017-02-10
US20080171079A1 (en) 2008-07-17
MY148464A (en) 2013-04-30
KR20070110413A (ko) 2007-11-16
HUS1800038I1 (hu) 2018-10-29
EP2301955A3 (en) 2011-11-16
LT2301955T (lt) 2018-07-10
MX2007010626A (es) 2007-10-16
PL2301955T3 (pl) 2018-08-31
MX346865B (es) 2017-04-04
NO20074392L (no) 2007-11-27
CN103028113B (zh) 2015-05-20
AR107285A2 (es) 2018-04-18
DK2281831T3 (en) 2018-06-14
PL2281831T3 (pl) 2018-08-31
PT2281830T (pt) 2017-02-24
WO2006094756A3 (en) 2007-02-15
JP5420842B2 (ja) 2014-02-19
HK1111427A1 (en) 2008-08-08
DK1858917T3 (da) 2015-02-02
HRP20150142T1 (hr) 2015-05-22
HUE038467T2 (hu) 2018-10-29
SI2281830T1 (sl) 2017-03-31
KR101357204B1 (ko) 2014-02-06
AU2006222225A1 (en) 2006-09-14
AU2006222225B2 (en) 2012-08-16
PL2281830T3 (pl) 2017-06-30
LT2281831T (lt) 2018-07-10
HRP20180988T1 (hr) 2018-08-10
CY1120347T1 (el) 2018-12-12
PT2281831T (pt) 2018-06-15
HUE032544T2 (en) 2017-10-30
JP2008531637A (ja) 2008-08-14
HRP20180989T1 (hr) 2018-08-10
EP2281830A2 (en) 2011-02-09
PL1858917T3 (pl) 2015-05-29
NO341841B1 (no) 2018-02-05
KR20140006115A (ko) 2014-01-15
DK2281830T3 (en) 2017-03-20
CN101189254A (zh) 2008-05-28
ES2675055T3 (es) 2018-07-06
US20110045059A1 (en) 2011-02-24
ES2532803T3 (es) 2015-03-31
BRPI0607840B1 (pt) 2021-06-29
LTPA2018012I1 (lt) 2018-11-12
NO2018033I1 (no) 2018-09-20
EP2301955A2 (en) 2011-03-30
SI1858917T1 (sl) 2015-03-31
NL300951I1 (nl) 2018-09-26
BRPI0607840A2 (pt) 2009-06-13
ES2618037T3 (es) 2017-06-20
CA2600905A1 (en) 2006-09-14
CN101189254B (zh) 2013-05-22
NZ561075A (en) 2009-06-26
US7939084B1 (en) 2011-05-10
EP1858917B8 (en) 2015-05-06
HUE038468T2 (hu) 2018-10-29
IL185442A0 (en) 2008-01-06
LTC2281831I2 (lt) 2020-08-25
TR201809393T4 (tr) 2018-07-23
EP2281830B1 (en) 2016-12-21
US20110104260A1 (en) 2011-05-05
EP1858917B1 (en) 2014-12-24
EP2281831B1 (en) 2018-04-18
TR201809397T4 (tr) 2018-07-23
UA94900C2 (uk) 2011-06-25
EP2281830A3 (en) 2012-01-25
CY1116108T1 (el) 2017-02-08
IL185442A (en) 2013-07-31
EP2301955B1 (en) 2018-04-18
NL300951I2 (nl) 2020-08-31
WO2006094756A2 (en) 2006-09-14
BE2018C035I2 (es) 2025-09-05
ZA200707144B (en) 2009-11-25
EP2281831A2 (en) 2011-02-09
CY2018025I2 (el) 2018-12-12
EP1858917A2 (en) 2007-11-28
HRP20170081T1 (hr) 2017-03-24
CA2600905C (en) 2015-05-05
JP5840167B2 (ja) 2016-01-06
CN103028113A (zh) 2013-04-10
ES2675054T3 (es) 2018-07-06

Similar Documents

Publication Publication Date Title
PE20100658A1 (es) COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y UN ADYUVANTE QUE CONTIENE QS21, COLESTEROL Y 3D-MPL
PE20161560A1 (es) Vacuna de pcsk9
NZ596870A (en) Vaccine compositions comprising a saponin adjuvant
ES2328474T3 (es) Preparacion de iscom y su utilizacion.
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
CO5700788A2 (es) Composiciones y metodos para inmunoterapia especifica de wt1
CO5700790A2 (es) Composiciones de vacuna que comprenden una interleucina 18 y sistema de adyuvante de saponina
UY27843A1 (es) Composicion de vacuna
CU23810A3 (es) Sustancias inmunogénicas que comprenden un adyuvante a base de ácido poliinosínico-ácido policitidílico
PE20142330A1 (es) Vacuna de peptido ch3 de ige
PE20080428A1 (es) Vacunas para la malaria
ES2195169T3 (es) Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion.
AR108718A2 (es) Composición
MX2022011155A (es) Inmunización activa de refuerzo contra tétanos, difteria y tosferina.
BRPI0606614A2 (pt) peptìdeos para distribuição de vacinas na mucosa
MX2010006207A (es) Vacuna.
WO2007101948A3 (fr) Nouveaux vaccins destines au traitement ou a la prevention des infections par parasites de la famille des taenidae et en particulier du genre echinococcus
CA2651764A1 (en) Hiv-1 immunogenic compositions
WO2007028985A3 (en) Adjuvanted vaccine
NZ611463A (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
AR033608A1 (es) Uso de una preparacion antigenica no viva trivalente de la gripe para la fabricacion de una vacuna de la gripe de una dosis para la liberacion intradermica y estuche farmaceutico que comprende dicha vacuna

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed